AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

Alexion has gained FDA approval for Kanuma, its treatment for the rare disease lysosomal acid lipase (LAL) deficiency. Alexion says Kanuma (sebelipase alfa) could eventually bring in more than $ ...

The partnership uses DHL GoGreen Plus, replacing traditional jet fuel with SAF. Credit: Deutsche Post AG. Alexion, AstraZeneca Rare Disease, and DHL Express have teamed up to initiate Ireland’s “first ...

Alexion, AstraZeneca Rare Disease, and DHL Express announced a partnership to reduce greenhouse gas emissions (GHG) from the air freight of highly specialised medicines manufactured in Ireland.

Alexion, AstraZeneca Rare Disease has become the first company in Ireland to switch 100% of its air freight of highly specialized medicines to sustainable aviation fuel (SAF), helping to reduce ...

(IN BRIEF) Alexion, AstraZeneca Rare Disease, has partnered with DHL Express to become the first company in Ireland to fully transition its air freight operations to 100% Sustainable Aviation Fuel ...

Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; ...

13, 2025 /PRNewswire/ -- Health industry leaders and advocates come together for The Boston Globe's Rare Disease Summit ... and The Pathway Initiative. Alexion is the presenting sponsor for ...